RxDoctor Payments Data

Jeanette Cochran

Nurse Practitioner · Angola, INNPI 1720305782

Payments from drug & device makers

$840in general payments, 2019–2025

Across 45 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$134
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$129
  • Otsuka America Pharmaceutical, Inc.$124
  • Supernus Pharmaceuticals, Inc.$110
  • Lundbeck LLC$99
  • Johnson & Johnson$61
  • plus $182 from 8 others

What the payments were for

  • Food & beverage$840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$4,347
Medicare patients
33
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine18$141,631
IngrezzaValbenazine Tosylate12$97,179
TrintellixVortioxetine Hydrobromide38$48,797
CaplytaLumateperone Tosylate24$45,301
AuvelityDextromethorphan Hbr/Bupropion31$45,135
VraylarCariprazine Hcl14$19,915
RexultiBrexpiprazole12$16,742
QuviviqDaridorexant Hcl19$9,019
Lamotrigine ErLamotrigine13$5,064
Aripiprazole42$3,135
Duloxetine Hcl123$3,068
Bupropion XlBupropion Hcl99$2,189
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$2,116
Ramelteon13$2,057
Gabapentin84$1,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$15$97,17912 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$24$48,79738 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$129$45,30124 claims
Axsome Therapeutics, Inc.Auvelity$134$45,13531 claims
AbbVieVraylar$50$19,91514 claims
Otsuka America Pharmaceutical, Inc.Rexulti$124$16,74212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Angola

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →